Autolus Therapeutics plc (6A3A) - Net Assets
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has net assets worth €74.84 Million EUR (≈ $87.49 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€493.23 Million ≈ $576.63 Million USD) and total liabilities (€418.39 Million ≈ $489.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Autolus Therapeutics plc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €74.84 Million |
| % of Total Assets | 15.17% |
| Annual Growth Rate | 2.82% |
| 5-Year Change | -43.15% |
| 10-Year Change | N/A |
| Growth Volatility | 104.66 |
Autolus Therapeutics plc - Net Assets Trend (2017–2025)
This chart illustrates how Autolus Therapeutics plc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 6A3A company net worth.
Annual Net Assets for Autolus Therapeutics plc (2017–2025)
The table below shows the annual net assets of Autolus Therapeutics plc from 2017 to 2025. Also explore 6A3A net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €178.13 Million ≈ $208.25 Million |
-58.32% |
| 2024-12-31 | €427.32 Million ≈ $499.59 Million |
+283.34% |
| 2023-12-31 | €111.47 Million ≈ $130.32 Million |
-62.68% |
| 2022-12-31 | €298.67 Million ≈ $349.18 Million |
-4.67% |
| 2021-12-31 | €313.32 Million ≈ $366.30 Million |
+49.18% |
| 2020-12-31 | €210.03 Million ≈ $245.55 Million |
-17.58% |
| 2019-12-31 | €254.84 Million ≈ $297.93 Million |
-0.25% |
| 2018-12-31 | €255.47 Million ≈ $298.67 Million |
+79.15% |
| 2017-12-31 | €142.60 Million ≈ $166.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Autolus Therapeutics plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 133885000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.56 Billion | 878.51% |
| Total Equity | €178.13 Million | 100.00% |
Autolus Therapeutics plc Competitors by Market Cap
The table below lists competitors of Autolus Therapeutics plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Helen of Troy Limited
F:HT2
|
$479.11 Million |
|
The York Water Company
NASDAQ:YORW
|
$479.15 Million |
|
First Trust High Yield Opportunities 2027 Term Fund
NYSE:FTHY
|
$479.15 Million |
|
Beijing Huaru Technology Co. Ltd.
SHE:301302
|
$479.20 Million |
|
Anhui Transport Consulting &
SHG:603357
|
$479.06 Million |
|
Jereissati Participações S.A.
SA:IGTI3
|
$479.03 Million |
|
Vastned Retail Belgium
BR:VASTB
|
$478.89 Million |
|
Radium Development Berhad
KLSE:5313
|
$478.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Autolus Therapeutics plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 427,325,000 to 178,129,000, a change of -249,196,000 (-58.3%).
- Net loss of 287,528,000 reduced equity.
- Other factors increased equity by 38,332,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-287.53 Million | -161.42% |
| Other Changes | €38.33 Million | +21.52% |
| Total Change | €- | -58.32% |
Book Value vs Market Value Analysis
This analysis compares Autolus Therapeutics plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.45x to 2.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €3.77 | €1.68 | x |
| 2018-12-31 | €6.36 | €1.68 | x |
| 2019-12-31 | €5.67 | €1.68 | x |
| 2020-12-31 | €4.01 | €1.68 | x |
| 2021-12-31 | €3.45 | €1.68 | x |
| 2022-12-31 | €1.73 | €1.68 | x |
| 2023-12-31 | €0.64 | €1.68 | x |
| 2024-12-31 | €1.61 | €1.68 | x |
| 2025-12-31 | €0.67 | €1.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Autolus Therapeutics plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -161.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -381.40%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 3.31x
- Recent ROE (-161.42%) is below the historical average (-71.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -13.83% | -1165.21% | 0.01x | 1.04x | €-33.99 Million |
| 2018 | -17.52% | -3180.60% | 0.01x | 1.07x | €-70.30 Million |
| 2019 | -48.60% | -4258.91% | 0.01x | 1.19x | €-149.33 Million |
| 2020 | -67.65% | -58716.53% | 0.00x | 1.40x | €-163.10 Million |
| 2021 | -45.35% | -6098.54% | 0.01x | 1.29x | €-173.43 Million |
| 2022 | -49.83% | -2402.95% | 0.01x | 1.64x | €-178.71 Million |
| 2023 | -186.93% | -12272.26% | 0.00x | 3.37x | €-219.53 Million |
| 2024 | -51.64% | -2180.45% | 0.01x | 1.83x | €-263.39 Million |
| 2025 | -161.42% | -381.40% | 0.13x | 3.31x | €-305.34 Million |
Industry Comparison
This section compares Autolus Therapeutics plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $723,315,608
- Average return on equity (ROE) among peers: -118.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Autolus Therapeutics plc (6A3A) | €74.84 Million | -13.83% | 5.59x | $479.09 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $-2.33 Million | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more